Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
FDA Approves High-Concentrate, Citrate-Free Formulation of Biosimilar Adalimumab-adbm
May 1st 2024The current approval is based on the VOLTAIRE-HCLF clinical trial, which examined the bioavailability of high-concentration (100 mg/mL) and low-concentration (50 mg/mL) formulations of adalimumab-adbm.
Read More
Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
April 18th 2024Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.
Read More
Patients with Fibromyalgia Scored Worse in Memory, Attention, Cognitive Function
April 11th 2024Without controlling for the severity of symptoms, patients with either fibromyalgia or RA performed worse when compared with controls in terms of cognitive domains including verbal memory, visual memory, and strategic planning.
Read More